Objective To evaluate the efficacy of Ketorolac Tromethamine injection versus Parecoxib sodium injection in

postoperative analgesia following transaxillary approach dual-plane prosthetic breast augmentation surgery. Methods A retrospective analysis was conducted on 91 patients with micromastia who underwent transaxillary approach dualplane implant breast augmentation surgery between December 2021 and September 2024. Patients were divided into two groups based on postoperative NSAIDs selection： the Ketorolac Tromethamine group （n=57） and the Parecoxib Sodium group （n= 34）. Postoperative pain VAS scores on days 1 and 2 were compared， and the incidence of adverse reactions such as nausea and vomiting was recorded. Results On postoperative day 1， the mean VAS score in the Ketorolac Tromethamine group was significantly higher than that in the Parecoxib Sodium group （6.40±2.17 vs. 4.44±2.60，P<0.05）. On postoperative day 2， no significant difference was observed between the groups （3.60±2.43 vs. 4.44±2.60，P>0.05）. The incidence of nausea on the first day post-operation was 7.7% （7/91）， the incidence of vomiting was 3.3% （3/91）， and there were no other adverse reactions. The incidence of nausea on the second day post-operation was 2.2% （2/91）， and there were no other adverse reactions. Conclusion Compared with Parecoxib Sodium， Ketorolac Tromethamine demonstrates superior analgesic efficacy in the early postoperative period for patients undergoing transaxillary approach dual-plane prosthetic breast augmentation.

Breast implant augmentation, Postoperative analgesia, Pain management, Nonsteroidal antiinflammatory drugs